FDA weighs loosening restrictions on experimental peptides amid safety concerns
Push backed by Robert F. Kennedy Jr., but scientists warn of limited safety data
FDA opens door to broader peptide access
The U.S. Food and Drug Administration is taking an early step toward potentially allowing compounding pharmacies to produce a set of experimental peptides previously restricted over safety concerns.
An agency advisory panel is expected to review seven peptides at a late-July meeting, considering whether they could be used in compounded drugs for conditions ranging from ulcerative colitis and wound healing to obesity and insomnia, the Washington Post reports.
The move signals a possible shift in how regulators handle a fast-growing — and controversial — corner of the health market.
Unproven, unregulated and coming to a market near you — the peptide gamble
Popularity surges ahead of science
Peptides, short chains of amino acids, have surged in popularity as “wellness” products marketed for anti-aging and performance benefits. But many of those claims remain unproven, and some compounds have not undergone rigorous clinical testing.
While certain peptide-based drugs — such as insulin and GLP-1 weight-loss medications — are FDA-approved, many newer injectable peptides are not.
The FDA in 2023 added several of these substances to a “do not compound” list, citing safety risks and lack of data.
Policy push meets safety warnings
Health Secretary Robert F. Kennedy Jr. has publicly supported expanding access, arguing that allowing regulated compounding could reduce risks tied to black-market products.
Kennedy — a self-declared “big fan” of peptide, saying treatments with the drug helped him recover from injuries, saying he got “good results.”
His position reflects growing pressure from patients and prescribers, who are increasingly seeking peptide therapies that are not commercially available.
But scientists caution that easing restrictions without stronger evidence could expose consumers to unknown harms.
“The dangers to the American public cannot be understated,” said Dr. Peter G. Lurie, president of the Center for Science in the Public Interest, in an email. “Not only would this unleash upon unsuspecting Americans a set of products previously deemed too dangerous to compound by the FDA, but it would also undermine the FDA drug approval process itself.
“What peptide manufacturer is going to conduct a multi-million-dollar drug research program and subject themselves to the rigors and uncertainties of the FDA drug approval system when they could simply start legally selling compounded peptides tomorrow?” Lurie asked.
“There’s just so little data,” said UC Davis biologist Paul Knoepfler, arguing that the full risks remain unclear.
“In light of the news today FDA under RFK Jr. is moving to unban unproven peptides via the compounding advisory committee, it’s still very odd that the DOJ just indicted someone related to many of these same peptides,” Knoepfler said in an X post today. Gray market complicates enforcement.
The case Knoepfler refers to involves a Utah doctor who allegedly made fake labels to sell Chinese-made peptides to more than 200 patients without telling them that the drugs had been made in China, the Salt Lake Tribune reported.
A booming market
Industry groups say demand has already fueled a booming gray market, where some vendors sell peptide products directly to consumers without prescriptions or oversight.
Compounding pharmacies, which are legally barred from producing restricted peptides, argue that the current rules may be unintentionally driving patients toward less regulated sources.
This is the same argument used by people who deal in illegal drugs like crack cocaine and heroin. They argue that their clients would buy their drugs legally if they were available.
The FDA is expected to continue evaluating additional peptides through at least 2027, suggesting a longer-term regulatory battle over how to balance access, safety and enforcement.
What this means
For consumers, the debate highlights a familiar trade-off: faster access to emerging therapies versus the protections that come with fully tested, FDA-approved drugs.
If restrictions are loosened, compounded peptides could become more widely available — but questions about safety, quality and effectiveness are likely to persist.